isoxazoles has been researched along with pelabresib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooper, MR; Eda, H; Mertz, JA; Panaroni, C; Raje, N; Ramachandran, J; Santo, L; Sims Iii, RJ; Siu, KT; Yee, AJ | 1 |
| Arnold, L; Raythatha, J | 1 |
| Järvenpää, J; Küblbeck, J; Lahtela-Kakkonen, M; Rahnasto-Rilla, M | 1 |
| Ferreira Gomes, G; Harrison, C | 1 |
1 review(s) available for isoxazoles and pelabresib
| Article | Year |
|---|---|
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis.
Topics: Antineoplastic Agents; Benzazepines; Humans; Isoxazoles; Primary Myelofibrosis | 2023 |
3 other study(ies) available for isoxazoles and pelabresib
| Article | Year |
|---|---|
Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
Topics: Animals; Benzazepines; Cell Cycle Proteins; G1 Phase Cell Cycle Checkpoints; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Isoxazoles; Mice; Multiple Myeloma; Nuclear Proteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Transcription Factors | 2017 |
The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis.
Topics: Benzazepines; Epigenesis, Genetic; Humans; Isoxazoles | 2019 |
Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.
Topics: Azepines; Benzazepines; Benzodiazepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Isoxazoles; Proteins; Sirtuins; Transcription Factors; Triazoles | 2022 |